Outcomes of the population included at the beginning of ECMO support
Death
Levosimendan was administered after a median of 5 days after starting ECMO, Q1–Q3 [3–6]. The duration of ECMO was longer in the levosimendan group (median duration of 11 days, Q1–Q3 [7–16] versus 6 days, [3.25–9]), as well as the length of the ICU stay (median duration of 18 days, Q1–Q3 [14–33] versus 13 days, Q1–Q3 [6–23.5]). Patients were more often successfully weaned from ECMO in the levosimendan group (39/65 (60.0%) versus 81/174 (46.6%)) at the end of follow-up. Death within 30 days following ICU admission occurred in 19/65 patients (29.3%) in the levosimendan group and 79/174 (45.4%) in the control group. Death within one year following ICU admission occurred in 27/60 patients (45.0%) in the levosimendan group and 94/172 (54.7%) in the control group. After one year, seven patients were lost to follow-up.